NIKKEI 225
38,312.50 +110.13 (+0.29%) HANG SENG
18,442.26 +128.40 (+0.70%) CRUDE OIL
79.31 +0.32 (+0.41%) GOLD FUTURES
2,316.40 -5.90 (-0.25%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,249.91 -970.96 (-1.93%)
Genprex, Inc. (GNPX)
After hours:
| Previous close | 2.4800 |
| Open | 2.4766 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2601 - 2.4799 |
| 52-week range | 2.0900 - 42.4000 |
| Volume | |
| Avg. volume | 51,968 |
| Market cap | 4.89M |
| Beta (5Y monthly) | -0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -22.5600 |
| Earnings date | 22 May 2024 - 26 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 165.00 |
PR NewswireGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of the Company's co-founder, President, Chairman and Chief Executive Officer (CEO), Rodney Varner, due to sudden complications after a courageous battle with cancer.
PR NewswireGenprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in May 2024.
- PR Newswire
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 America
